Announcement

Collapse
No announcement yet.

China - CDC director says domestic COVID-19 vaccines have low efficacy, may mix them - April 11, 2021

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • China - CDC director says domestic COVID-19 vaccines have low efficacy, may mix them - April 11, 2021


    Top official admits China's COVID-19 vaccines have low efficacy

    Social Sharing

    Government considering mixing doses to get a boost, China's CDC director says

    The Associated Press · Posted: Apr 11, 2021 9:48 PM ET | Last Updated: 35 minutes ago

    In a rare admission of the weakness of coronavirus vaccines developed in China, the country's top disease control official says their effectiveness is low and the government is considering mixing them to get a boost.

    China's vaccines "don't have very high protection rates," Gao Fu, the director of China's Centers for Disease Control, said at a conference Saturday in the southwestern city of Chengdu.

    Beijing has distributed hundreds of millions of doses abroad while trying to promote doubt about the effectiveness of the Pfizer-BioNTech vaccine made using the previously experimental messenger RNA, or mRNA, process.

    "It's now under formal consideration whether we should use different vaccines from different technical lines for the immunization process," Gao said.

    more..

    https://www.cbc.ca/news/health/china...983594?cmp=rss

  • #2
    "Everyone should consider the benefits mRNA vaccines can bring for humanity," Gao said. "We must follow it carefully and not ignore it just because we already have several types of vaccines already."
    _____________________________________________

    Ask Congress to Investigate COVID Origins and Government Response to Pandemic H.R. 834

    “‘i love myself.’ the quietest. simplest. most powerful. revolution ever.” ---- nayyirah waheed

    (My posts are not intended as advice or professional assessments of any kind.)
    Never forget Excalibur.

    Comment


    • #3
      China, which has mastered the epidemic without abusing vaccines on the one hand, and on the other hand with its one-child policy and serial vaccinations, is in a position to make its choices. It has proven its ability to control certain influenzas by vaccines.

      It is in a situation and needs to find sustainable solutions, given its objectives, in particular the land silk route. This situation could allow Russian cooperation, which is essential in practice.
      She has the skills and the finances to do whatever she wants. Why not RNA vaccines, but the choice made in the USA of the intramuscular route will be the route chosen?

      Comment


      • #4
        Originally posted by bertrand789 View Post
        China, which has mastered the epidemic without abusing vaccines on the one hand, and on the other hand with its one-child policy and serial vaccinations, is in a position to make its choices. It has proven its ability to control certain influenzas by vaccines.

        It is in a situation and needs to find sustainable solutions, given its objectives, in particular the land silk route. This situation could allow Russian cooperation, which is essential in practice.
        She has the skills and the finances to do whatever she wants. Why not RNA vaccines, but the choice made in the USA of the intramuscular route will be the route chosen?
        You can not assume anything about China's infectious disease status.

        Comment


        • bertrand789
          bertrand789 commented
          Editing a comment
          correct, but is that the question?

      • #5
        Source: https://www.scmp.com/news/china/scie...alf-study-says

        Sinovac shot cuts risk of symptomatic Covid-19 in half, study says
        Primary efficacy rate found to be 50.7 per cent, according to results of final-stage trial in Brazil
        Separate study, also in Brazil, finds product to be almost 50 per cent effective at curbing the infection risk of the P1 variant
        Linda Lew
        Published: 4:06pm, 12 Apr, 2021

        Chinese drug maker Sinovac’s CoronaVac shot reduces the risk of symptomatic Covid-19 infections by half, in line with previous data, according to the long-awaited results of a phase three clinical trial in Brazil.

        The trial by Brazil’s state-owned research institute Butantan involved 9,823 health care workers, who received two doses of the vaccine. The primary efficacy against symptomatic Covid-19 infection was 50.7 per cent, according to the study, which was published on Sunday but has not yet been peer reviewed.

        “This pivotal trial for CoronaVac was able to demonstrate the safety and efficacy of a new Covid-19 vaccine,” the study said.

        The efficacy rate of the Sinovac inactivated vaccine, which uses dead material from the virus to trigger an immune response, is lower than mRNA vaccines from Western drug makers such as BioNTech-Pfizer and Moderna, whose products have been shown to be over 90 per cent effective...

        ...Gao Fu, the director of the Chinese Centre for Disease Control and Prevention, said on Saturday that the authorities were considering two options to “solve the problem ” of low efficacy: adjusting dosages and mixing different products.

        However, in an interview with state-backed tabloid Global Times on Sunday, Gao said his remarks – made at a health conference – had been misunderstood. How to improve the efficacy of vaccines was something that needed to be considered by scientists around the world, he said.


        In a positive development for Sinovac, a separate study in Brazil found its product to be almost 50 per cent effective at curbing the infection risk of the P1 Covid-19 variant that was first identified in the South American country...

        Comment


        • #7
          What do we know about China’s covid-19 vaccines?

          BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n912 (Published 09 April 2021)Cite this as: BMJ 2021;373:n912
          Read our latest coverage of the coronavirus outbreak
          1. Chris Baraniuk
          1. Author affiliations
          1. chrisbaraniuk@gmail.com

          The country where covid-19 first emerged is championing a string of vaccines, both domestically and abroad. But opacity surrounding data makes for a fractured picture, reports Chris Baraniuk

          What vaccines has China developed?


          There are about a dozen Chinese vaccine candidates for covid-19, but five front runners have received emergency use approval in China as well as several other countries.

          Sinopharm, a state owned enterprise, is currently working on two different jabs, both of which are based on an inactivated form of SARS-CoV-2. The first was developed at Sinopharm’s Beijing institute while the second was developed in Wuhan. A third vaccine called CoronaVac was developed by the Beijing based pharmaceutical firm Sinovac. It is also based on an inactivated form of SARS-CoV-2.

          All three of these require two doses but the fourth front runner, from vaccine developer CanSinoBIO, is single dose. Unlike the others, it uses a human adenovirus, Ad5, to deliver SARS-CoV-2 proteins into the body. (Russia’s Sputnik V vaccine also uses a form of Ad5 as well as another adenovirus.) CanSinoBIO previously used the same approach to develop an Ebola vaccine that was approved for emergency use in China.

          A fifth vaccine candidate,1 from pharmaceutical firm Anhui Zhifei Longcom, was given emergency use approval on 16 March. This one requires three doses and uses proteins based on the receptor binding domain of the SARS-CoV-2 virus.

          All five of these vaccines can be kept at normal fridge temperatures, a big advantage over others that require storage at extremely cold temperatures.

          What clinical trial data are there?


          Randomised, double blinded phase I and II trial results for CoronaVac in two age groups—18-59 and 60 and over—were published in the Lancet in November2 and February,3 respectively. The trials found immunogenicity in most patients and that the vaccine was generally safe and well tolerated, with few adverse effects. Phase I and II data for the Anhui Zhifei Longcom vaccine published in March4 showed similar results.

          At the time of writing, no phase III trial data for any of the Chinese vaccine candidates have been published in a peer reviewed journal. CanSinoBIO has said it intends to but has given no timeframe.

          Most of what we know comes from announcements from the manufacturers and the governments in countries where trials are being conducted. Sinopharm claimed in December that its first vaccine was 79% effective in terms of preventing symptomatic covid-19, based on interim phase III data.5 That is lower than the 86% efficacy reported earlier the same month by the United Arab Emirates,6 one of the countries in which the vaccine has been trialled. Other countries trialling the jab include Bahrain, Egypt, Jordan, and Peru. Sinopharm has also said its second vaccine, from the Wuhan institute, was found to be slightly less effective at 72.5%, based on interim data from phase III trials.7

          Also in December, Turkish officials reported interim data from trials showing that Sinovac’s CoronaVac was 91.25% efficacious at preventing symptomatic covid-19 among a subgroup of 1322 participants in a trial involving 7371 people.8 But in January, researchers in Brazil announced that the CoronaVac jab was 78% effective at preventing mild cases, according to information from a phase III trial involving 12?000 healthcare workers in the country.9 Just a week later, additional data emerged, taking into account very mild cases and suggesting that the vaccine was only 50.4% effective against symptomatic covid-19.10 In the same month, authorities in Indonesia said the vaccine, which is being trialled there too, was 65% effective.11

          CanSinoBIO’s one dose jab was found to be 75% effective in Pakistan, according to officials there.12 The vaccine is also being trialled in Argentina, Chile, Mexico, and Russia.13

          The Associated Press has reported that, according to preliminary data sent to China’s drug regulators, Sinovac is safe for children aged 3 to 17 based on early and mid-stage trials of over 550 subjects.14

          How much do they cost?


          In December, state media in China reported that Sinopharm and Sinovac intended to charge the government roughly $30 (£22; €26) per dose of their vaccines.15 Detail about the cost of other vaccines developed in China has not been made public.

          How are the vaccines being deployed in China?


          All five of the leading domestic candidates can be used in China, though it’s unclear how many doses of each have been administered so far, or where. No other vaccines have been approved for use in China.

          The country had administered around 120 million doses as of 31 March, according to data published by the National Health Commission and reported by Reuters.16 Zhong Nanshan, a former president of the Chinese Medical Association, told the news agency in early March that China is aiming to vaccinate 40% of its 1.4 billion population by the end of July.17 The country is prioritising 18 to 59 year olds in key worker groups, such as healthcare workers, before moving on to clinically vulnerable people and then those who are aged 60 or over.18

          Authorities behind Hong Kong’s mass free vaccination programme have said that three centres originally set to offer the Pfizer vaccine would switch to Sinovac in response to strong public demand to be vaccinated as soon as possible.

          Because of the lack of transparency surrounding Chinese made vaccines, however, vaccine hesitancy appears to be a problem. A survey by China’s disease control and prevention centre found that just 42% of healthcare and epidemic preparedness workers were willing to have a vaccine during a recent rollout.19 There are reports of similar hesitancy in Brazil; in a recent poll in the country, just 47% of respondents said they would be willing to take a vaccine made in China.20

          Which of China’s vaccines have been approved outside of China?


          Sinopharm’s first vaccine has received the most emergency use approvals so far, nearly 30, including in Bahrain, Guyana, Hungary, Serbia, and the UAE. Hungary was the first EU country to approve use of a Chinese vaccine, with Prime Minister Viktor Orbán among those who have received it.

          Several countries have approved Sinovac’s CoronaVac jab for emergency use, including Brazil, Chile (where the vaccine has been trialled), Indonesia, Laos, Mexico, and Turkey.

          Mexico and Pakistan have given emergency use approval to the CanSinoBIO vaccine.

          The Anhui Zhifei Longcom vaccine has received approval for use in Uzbekistan.

          Which countries have received Chinese vaccines?


          Chinese firms have appeared keen to supply countries with plenty of doses of their vaccines, beyond those merely required to carry out clinical trials. For example, 223 million doses of Sinopharm jabs have already been distributed to various countries around the world. In some countries, the value of deals remains undisclosed but the New York Times reported that Hungary paid $36 per dose for the Sinopharm jab.21 In Senegal, a lower price was achieved22—just $19 per dose in a deal supplying 200?000 Sinopharm doses to the African country.

          Some nations are relying heavily on Chinese vaccines for their covid-19 vaccination programmes. The majority of those administered by the UAE, for example, are made by Sinopharm. Serbia looks set to receive another 500?000 Sinopharm doses, having already taken delivery of 1.5 million. Cambodia and Egypt have received shipments of 300?000 doses at a time.

          Meanwhile, countries trialling Sinovac’s vaccine have received large numbers of doses already. Indonesia, for instance, has had 28 million doses at the time of writing. Chile has received five shipments according to China’s state media23 although the exact number of doses is unclear.

          Rollout of the CanSinoBIO vaccine has only just started, but Pakistan has ordered “tens of millions” of doses, according to its health minister.24 Mexico has ordered eight million doses of the same jab.

          Footnotes
          • Commissioned, not peer reviewed
          ...

          https://www.bmj.com/content/373/bmj.n912
          "Safety and security don't just happen, they are the result of collective consensus and public investment. We owe our children, the most vulnerable citizens in our society, a life free of violence and fear."
          -Nelson Mandela

          Comment


          • #8
            i am bitter

            I am bitter, because out of respect for life and work, the reflection was more advanced.

            Seen this:
            The next step for Covid-19 vaccines may be through the nose
            https://www.smithsonianmag.com/scien...2lS6E.linkedin
            so the strategy is two intramuscular vaccines, followed by a mucosal vaccine.

            https://zh.wikipedia.org/wiki/%E5%B0%8A%E9%87%8D

            I am thinking of those workers, who work with animals, in production, during transport and / or sale, live birds. The mucous membrane is not already in place, why?
            In vet the birds hatch, vaccinate
            https://patents.justia.com/patent/10130701

            All these companies that produce poultry, will one day worry about their staff in China or elsewhere?

            Comment


            • #9
              bump this

              Comment

              Working...
              X